What is a stock summary page? Click here for an overview.
Business Description
Hangzhou Tigermed Consulting Co Ltd
ISIN : US41044T1088
Share Class Description:
HNGZY: ADRCompare
Compare
Traded in other countries / regions
300347.China03347.Hong Kong5HZ1.GermanyHNGZY.USA IPO Date
2020-12-01Description
Hangzhou Tigermed Consulting Co Ltd is a China-based Contract Research Organization. The company's segment includes Clinical trial solutions and Clinical-related and laboratory services. It generates maximum revenue from the Clinical trial solutions segment. The company's offered services include bioanalytical, medical writing, biostatistics analysis, and medical imaging. The therapeutic areas of the company include Infections, Hematology, Cardiovascular, Endocrinology, Rheumatology, Nephrology, and Central Nervous System (CNS) among others.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.75 | |||||
| Equity-to-Asset | 0.72 | |||||
| Debt-to-Equity | 0.14 | |||||
| Debt-to-EBITDA | 3.52 | |||||
| Interest Coverage | 13.69 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 6.25 | |||||
| Beneish M-Score | -2.34 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 8.6 | |||||
| 3-Year EBITDA Growth Rate | -33.6 | |||||
| 3-Year EPS without NRI Growth Rate | -11.1 | |||||
| 3-Year FCF Growth Rate | -10.8 | |||||
| 3-Year Book Growth Rate | 4.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 23.25 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 10.07 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 6-1 Month Momentum % | -3.38 | |||||
| 12-1 Month Momentum % | -4.76 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.72 | |||||
| Quick Ratio | 1.71 | |||||
| Cash Ratio | 0.58 | |||||
| Days Inventory | 2.06 | |||||
| Days Sales Outstanding | 70.8 | |||||
| Days Payable | 20.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Payout Ratio | 0.62 | |||||
| 3-Year Dividend Growth Rate | 23.7 | |||||
| 3-Year Average Share Buyback Ratio | 0.3 | |||||
| Shareholder Yield % | 0.31 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 33.95 | |||||
| Operating Margin % | 16.17 | |||||
| Net Margin % | 6.14 | |||||
| FCF Margin % | 11.23 | |||||
| ROE % | 1.94 | |||||
| ROA % | 1.36 | |||||
| ROIC % | 2.9 | |||||
| 3-Year ROIIC % | -4.84 | |||||
| ROC (Joel Greenblatt) % | 51.46 | |||||
| ROCE % | 3.18 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 108.47 | |||||
| Forward PE Ratio | 16.81 | |||||
| PE Ratio without NRI | 54.7 | |||||
| Shiller PE Ratio | 37.3 | |||||
| Price-to-Owner-Earnings | 421.32 | |||||
| PS Ratio | 6.66 | |||||
| PB Ratio | 2.13 | |||||
| Price-to-Tangible-Book | 2.58 | |||||
| Price-to-Free-Cash-Flow | 59.07 | |||||
| Price-to-Operating-Cash-Flow | 39.95 | |||||
| EV-to-EBIT | 57.26 | |||||
| EV-to-Forward-EBIT | 9.85 | |||||
| EV-to-EBITDA | 57.26 | |||||
| EV-to-Revenue | 6.99 | |||||
| EV-to-Forward-Revenue | 5.66 | |||||
| EV-to-FCF | 62.31 | |||||
| Price-to-GF-Value | 0.78 | |||||
| Price-to-Projected-FCF | 1.53 | |||||
| Price-to-Median-PS-Value | 0.5 | |||||
| Price-to-Graham-Number | 2.5 | |||||
| Earnings Yield (Greenblatt) % | 1.75 | |||||
| FCF Yield % | 1.79 | |||||
| Forward Rate of Return (Yacktman) % | -0.67 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:HNGZY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Hangzhou Tigermed Consulting Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 917.071 | ||
| EPS (TTM) ($) | 0.065 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 4.23 | ||
| 14-Day RSI | - | ||
| 14-Day ATR ($) | 0.000088 | ||
| 20-Day SMA ($) | 4 | ||
| 12-1 Month Momentum % | -4.76 | ||
| 52-Week Range ($) | 4 - 4.3 | ||
| Shares Outstanding (Mil) | 864.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hangzhou Tigermed Consulting Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Hangzhou Tigermed Consulting Co Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Hangzhou Tigermed Consulting Co Ltd Frequently Asked Questions
What is Hangzhou Tigermed Consulting Co Ltd(HNGZY)'s stock price today?
The current price of HNGZY is $4.00. The 52 week high of HNGZY is $4.30 and 52 week low is $4.00.
When is next earnings date of Hangzhou Tigermed Consulting Co Ltd(HNGZY)?
The next earnings date of Hangzhou Tigermed Consulting Co Ltd(HNGZY) is .
Does Hangzhou Tigermed Consulting Co Ltd(HNGZY) pay dividends? If so, how much?
Hangzhou Tigermed Consulting Co Ltd(HNGZY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers